The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
Open accessAbstract
BACKGROUND: Biliary tract cancers (BTC) are relatively rare malignant tumours with poor prognosis. It is known from other solid neoplasms that antitumour inflammatory response has an impact on tumour behaviour and patient outcome. The aim of this study was to provide a comprehensive characterisation of antitumour inflammatory response in human BTC. METHODS: Tumour-infiltrating T lymphocytes (CD4+, CD8+, and Foxp3+), natural killer cells (perforin+), B lymphocytes (CD20+), macrophages (CD68+) as well as mast cells (CD117+) were assessed by immunohistochemistry in 375 BTC including extrahepatic (ECC; n=157), intrahepatic (ICC; n=149), and gallbladder (GBAC; n=69) adenocarcinomas. Overall and intraepithelial quantity of tumour-infiltrating immune cells was analysed. Data were correlated with clinicopathological variables and patient survival. RESULTS: The most prevalent inflammatory cell type in BTC was the T lymphocyte. Components of the adaptive immune response decreased, whereas innate immune response components increased significantly in the biliary intraepithelial neoplasia - primary carcinoma - metastasis sequence. BTC patients with intraepithelial tumour-infiltrating CD4+, CD8+, and Foxp3+ T lymphocytes showed a significantly longer overall survival. Number of total intraepithelial tumour-infiltrating Foxp3+ regulatory T lymphocytes (HR: 0.492, P=0.002) and CD4+ T lymphocytes (HR: 0.595, P=0.008) were tumour grade- and UICC-stage-independent prognosticators. The subtype-specific evaluation revealed that the tumour-infiltrating lymphocytic infiltrate is a positive outcome predictor in ECC and GBAC but not in ICC. CONCLUSION: Our findings characterise the immune response in cholangiocarcinogenesis and identify inflammatory cell types that influence the outcome of BTC patients. Further, we show that BTC subtypes show relevant differences with respect to density, quality of inflammation, and impact on patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Clinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2004) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q., Lonning, S., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Self-citationCholangiocarcinoma—controversies and challenges
Patel, T. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.20 · Cited by 337
Komuta, M., Govaere, O., Vandecaveye, V., Akiba, J., Van Steenbergen, W., Verslype, C., Laleman, W., Pirenne, J., Aerts, R., Yano, H., et al. (2012) · Hepatology · doi:10.1002/hep.25595 · Cited by 333
Sinicrope, F. A., Rego, R. L., Ansell, S. M., Knutson, K. L., Foster, N. R., & Sargent, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.053 · Cited by 329
Cho, Y., Miyamoto, M., Kato, K., Fukunaga, A., Shichinohe, T., Kawarada, Y., Hida, Y., Oshikiri, T., Kurokawa, T., Suzuoki, M., et al. (2003) · PubMed · Cited by 278
Meissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., & Seliger, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2146 · Cited by 266
Kubota, H., & Reid, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.12132 · Cited by 241
Diederichsen, A. C. P., v. B. Hjelmborg, J., Christensen, P. B., Zeuthen, J., & Fenger, C. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0388-5 · Cited by 237
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 210
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., Sengupta, S., Dong, H., Cheville, J. C., Lohse, C. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2139 · Cited by 202
Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors
Cardinale, V. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i11.407 · Cited by 197
Ogino, T., Shigyo, H., Ishii, H., Katayama, A., Miyokawa, N., Harabuchi, Y., & Ferrone, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0488 · Cited by 189
Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors
Facoetti, A., Nano, R., Zelini, P., Morbini, P., Benericetti, E., Ceroni, M., Campoli, M., & Ferrone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2588 · Cited by 184
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 165
Han, L. Y., Fletcher, M. S., Urbauer, D. L., Müeller, P. R., Landen, C. N., Kamat, A. A., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Deavers, M. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4433 · Cited by 153
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.
Natali, P. G., Nicotra, M., Bigotti, A., Venturo, I., Marcenaro, L., Giacomini, P., & Russo, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6719 · Cited by 146
Colon cancer and the immune system: The role of tumor invading T cells
Waldner, M. J., Schimanski, C.-C., & Neurath, M.-F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i45.7233 · Cited by 111
Oshikiri, T., Miyamoto, M., Shichinohe, T., Suzuoki, M., Hiraoka, K., Nakakubo, Y., Shinohara, T., Itoh, T., Kondo, S., & Katoh, H. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10321 · Cited by 104
Yoon, H. H., Orrock, J. M., Foster, N. R., Sargent, D. J., Smyrk, T. C., & Sinicrope, F. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042274 · Cited by 101
Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas
Guedj, N., Zhan, Q., Périgny, M., Rautou, P., Degos, F., Belghiti, J., Farges, O., Bédossa, P., & Paradis, V. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.017 · Cited by 89
Dendritic cells, T-cell infiltration, and grp94 expression in cholangiocellular carcinoma
TAKAGI, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.03.016 · Cited by 87
Hepatic Progenitor Cells: An Update
Roskams, T., Katoonizadeh, A., & Komuta, M. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.08.003 · Cited by 79
Novel insights into the molecular mechanisms of HLA class I abnormalities
Seliger, B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1153-9 · Cited by 70
The immunoregulatory mechanisms of carcinoma for its survival and development
Du, C., & Wang, Y. Z. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-12 · Cited by 69
Kasajima, A., Sers, C., Sasano, H., Jöhrens, K., Stenzinger, A., Noske, A., Buckendahl, A., Darb‐Esfahani, S., Müller, B. M., Budczies, J., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.014 · Cited by 67
Self-citationMathai, A. M., Kapadia, M. J., Alexander, J., Kernochan, L. E., Swanson, P. E., & Yeh, M. M. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824e9b7c · Cited by 65
Characterization of hepatic progenitors from human fetal liver during second trimester
Rao, M. S., Khan, A. A., Nyamath, P., Habeeb, M. A., Habibullah, C. M., & Pande, G. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5730 · Cited by 47
Gene selection in microarray survival studies under possibly non-proportional hazards
Dunkler, D., SCHEMPER, M., & Heinze, G. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq035 · Cited by 31
Humphreys, E. H., Williams, K. T., Adams, D., & Afford, S. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014037 · Cited by 28
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Wouters, M. C. A., & Nelson, B. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1481 · Cited by 495
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
Metadata
- Authors
- Goeppert, B., Frauenschuh, L., Zucknick, M., Stenzinger, A., Andrulis, M., Klauschen, F., Joehrens, K., Warth, A., Renner, M., Mehrabi, A., Hafezi, M., Thelen, A., Schirmacher, P., & Weichert, W.
- Venue
- British Journal of Cancer
- Published
- 2013-10-17
- Volume
- 109
- Issue
- 10
- Pages
- 2665-2674
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2005501957
- Cited by
- 275
- References
- 46
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.